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Prognostic value of steroid receptors after long-term follow-up of 2257
operable breast cancers
MF Pichon, P Broet, H Magdelenat, JC Delarue, F Spyratos, JP Basuyau, S Saez, A Rallet,
P Courriere, R Millon and B Asselain
Groupe de Biopathologie Tissulaire et Moleculaire, Federation des Centres de Lutte contre le Cancer, 101 rue de Tolbiac, 75654
Paris Cedex 13, France.
S_inary The prognostic value of oestrogen receptor (ER) and progesterone receptor (PR) was estimated
through a multicentric study of 2257 operable breast cancer patients followed up for a median of 8.5 years.
None ofthe patients had received adjuvant therapy. The series included 33.3% stage I patients, 57.1% stage II,
5.7% stage Hila and 2.4% stage IIIb. At the end point ofthe study 589 metastases and 537 deaths from cancer
were recorded. Receptor measurements were performed by radioligand assay according to a uniform protocol.
A total of68.8% ofthe tumours were ER positive and 54.0% PR positive (> 10 fmol mg-I cytosol protein). In
univariate analysis, ER and PR status (positive/negative) were of prognostic value (P<0.001) for the disease-
free interval (DFI), the metastases-free interval (MFI) and the overall survival (OS). The OS of the patients
after a first metastasis was also significantly different between ER-positive and -negative tumours (P<O.001). In
multivariate analysis (Cox proportional hazard model, 1665 patients), only the ER status showed a significant
difference (P<0.01) between positive and negative groups regarding the DFI, MFI and OS. By using Cox non-
proportional, time-dependent models, we show that the predictive value of ER status of the primary tumour
decreases by approximately 20% per year, losing its significance after 8 years of follow-up. Overall, when
compared with TNM and histological grading, ER and PR status have a low prognostic value, their major
interest rmaining solely in the domain of therapeutic decision.
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The majority of the studies on steroid receptors and
prognosis of early breast cancer have found a positive
correlation between the receptor status and patients' out-
come.
Several lines of data suggest that the expression of
oestrogen and progesterone receptors in the primary tumour
is related to the degree of differentiation of the tumour and
its proliferation rate. The prognostic value of steroid
receptors is probably linked to this relationship.
Nevertheless, many discrepant results have been published
relating to the actual prognostic value of steroid receptors.
Several reports show that, with increasing follow-up, the
initial advantage of positive receptor assays in terms of
disease-free interval and survival vanishes (review in
Raemaekers et al., 1985).
To address this question we set up a multicentric study of
patients diagnosed and treated for primary breast cancer
from the beginning of the 1970s. None of the patients had
received adjuvant therapy, and receptor assays were all
performed using radioligand techniques according to French
national protocol (Martin et al., 1981).
Patient and methosi
Patients
The 2257 patients were diagnosed and treated between the
beginning of 1974 and the end of 1984 at eight different
cancer centres, and the results of their follow-up were studied
up to September 1993. The median follow-up time was 8.5
years. At 5 years 7.7% of the patients were lost to follow-up.
Bilateral cancers and patients with any kind of adjuvant
therapy were excluded from the study.
Information was recorded for each patient including age
and hormonal status at diagnosis, clinical stage, histological
classification and grade, pathological size and axillary lymph
nodes status, steroid receptor status, as well as primary
treatment (Table I).
The mean age of the patients was 59 years (range 20-98
years) and 74 patients (3.3%) were under 35 years. Sixty-five
per cent of the patients were post-menopausal (range between
centres 14-44%). Significant differences (P<0.0001) in the
mean ages (range 55-65 years) and in the proportion of
menopausal patients (range 14-44%) were also observed
between centres.
Staging of the disease was performed according to the
UICC criteria (stage I, 33.3%; stage II, 57.1%; stage IIIa,
5.7% and 2.4% stage IIb) (Table I). Significant differences
(P<0.0001) in the proportions of the different stages were
also observed between centres (range 13-55% for stage I and
44-68% for stage II). The primary treatment was
tumorectomy (32.7%) or mastectomy with axillary dissection
(67.3%), followed by radiotherapy for 49.4% of cases.
Complete follow-up histories of the patients were
recorded. During the first year, the follow-up was conducted
at 3 month intervals, then over the following 2 year period at
6 month intervals, and thereafter annually.
Methods
Histology Tumour size was recorded as the maximum
diameter of the surgically removed tumour mass. Axillary
lymph nodes status (mean number examined: 13) was
assessed by histological examination for 2045 patients.
Grading of the tumours was performed according to the
Scarff, Bloom and Richardson method (SBR) (Bloom and
Richardson, 1957).
Steroid receptors assays Cytosol oestrogen (ER) and
progesterone (PR) receptors were measured by the dextran-
coated charcoal assay with tritiated ligands (Martin et al.,
1981). Before the development of a national quality control
in 1981, subsequently linked to the EORTC (European
Organization for Research and Treatment of Cancer) quality
control, all participants used internal quality controls made
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Table I Population characteristics
Characteristics Number (%) ofpatients
Age
Mean (years) 59
Range (min, max) 20-98
Hormonal status
Premenopausal 791 (35.0)
Post-menopausal 1466 (65.0)
TNM stage
I 752 (33.3)
H 1290 (57.1)
Illa 130 (5.7)
Hb 56 (2.4)
ND 29 (1.5)
Tumour size (mm)
<20 964 (42.7)
20 to 50 1038 (46.0)
>50 163 (7.2)
ND 92 (4.1)
Histology
Ductal 1849 (82.0)
Lobular 105 (4.6)
Other histology 303 (13.4)
Histological grade (SBR)
I 466 (20.6)
HI 1144 (50.7)
Im 402 (17.8)
ND 245 (10.9)
Axillary lymph nodes (pN)
None 1511 (66.9)
1-3 443 (19.6)
.4 91 (4.0)
ND 212 (9.5)
ER
Negative 571 (25.3)
Positive 1554 (68.8)
ND 132 (5.9)
PR
Negative 948 (42.0)
Positive 1218 (54.0)
ND 91 (4.0)
ND, not determined; ER, oestrogen receptors; PR, progesterone
receptors. Positivity if > 10 fmol mg Icytosol protein.
of powders from rabbit or rat uterine tissues kept in liquid
nitrogen. Comparisons of the results from exchanged series of
tumour tissues were also performed by the members of the
group. The cut-off level for receptor positivity was
10 fmol mg-' cytosol protein for both receptors.
Statistical methods Comparisons between steroid receptors
and clinical and histological data were performed by using
standard XJ tests in the relevant contingency tables. Two-
sided P-values under 0.05 were considered significant.
Disease-related deaths were scored as an event with
censoring of the other patients for non-cancer-related death
at the time of last follow-up. The disease-free interval was
calculated from the date of the first treatment. First
recurrence or first metastasis were scored as an event,
censoring the other patients at the time of the last follow-
up or of death. Local recurrence was defined as tumour
arising in the treated breast or as a nodal recurrence. Survival
curves were derived from Kaplan-Meier estimates (Kaplan
and Meier, 1958). Survival rates are presented with their
standard deviation (±s.d.). The prognostic value of ER or
PR was tested using the log-rank test (Peto and Peto, 1972),
with an estimation of their unadjusted risk ratio.
The influence of ER and PR on prognosis, adjusted for the
other prognostic factors, was assessed in a multivariate
analysis by the Cox proportional hazard regression model in
a forward stepwise procedure (Cox, 1972). The survival time
of each patient was assumed to be following its own hazard
function expressed as h(t)=ho(t) exp (bZ) where ho(t) is an
unknown hazard function, Z the vector of measured values
of the covariates for the patient, and b the vector of
regression coefficients associated with these covanates. The
b coefficients produced by the analysis show how much each
factor contributes to the hazard. Complete data for all
clinical and biological variables were available for 1665 out of
2257 patients. Therefore, the Cox model used this subset of
1665 patients. Confounding variables with k subgroups were
coded to (k- 1) dummy variables. This model assumes a log-
linear relation of relative risks between two subsequent
subgroups when k>2. The relative risks (RRs) are presented
with their confidence interval (CI). The classical Cox
proportional hazard model implies that the effect of ER
concentration is constant throughout the patient's survival
experience. To take into account possible violations of this
assumption, a separate approach was used by modelling a
time-dependent relation between hazard and covariates (Cox
model with time-dependent covariates, amended by Kalb-
fleish and Prentice, 1980). To accommodate this time
dependency, receptor status was entered as a time-dependent
covariate in the amended model h(t)=ho(t). exp ([b'+b"
f(t)]Z) with two functions of time: fit)=time and fit)=Ln
(time). Annual relative risks, calculated by using the time-
dependent hazard function are presented on the same figure
as the model curves. All statistical analyses were performed
by using BMDP programs.
Resuhs
Histopathology and receptors
The mean size of the tumours was 28.9 mm (range between
centres 20.4-35.6 mm). A total of 1511 (66.9%) patients
were node negative, 443 (19.6%) had 1-3 invaded nodes, 91
(4.0%) more than four invaded nodes (range between centres
for node-negative patients 42-100%). Eighty-two per cent
were ductal carcinomas, 4.6% were lobular carcinomas, the
other particular histological types were recorded as a whole
group (13.4%). In all 20.6% were SBR grade I (range
between centres 14-53%), 50.7% were SBR grade II (range
21-70%), 17.8% were SBR grade III (range 9-36%) (Table
I). Significant variations in the mean tumour size, propor-
tions of positive or negative lymph nodes and in the three
SBR groups were observed between different centres
(P<0.001).
Some 68.8% of the tumours were ER positive (mean
concentration 93 fmol mg-' cytosol protein), 54.0% were PR
positive (mean concentration 73 fmol mg-' protein). For 223
cases only one receptor could be measured because of
insufficient tumour tissue. Positivity for both receptors was
observed in 53.3% of the tumours, 23.9% were all negative,
19.8% were only ER positive and 3.0% only PR positive.
Table H summarises the results of receptor assays from the
participating centres.
Receptor status and patients characteristics (Table III).
ER was significantly related to: age (P=0.005), menopausal
status (P=0.005), lymph node involvement (P=0.03),
tumour size (P=0.04), histological type of the tumour
(P=0.0001) and SBR grade (P=0.001). PR was significantly
related to clinical stage (P=0.001), lymph node involvement
(P=0.015), tumour size (P=0.04), histological type
(P=0.0001) and grade (P=0.001).
Patients' outcome
At the end point of our study, we have recorded 307 local
recurrences, 589 metastases and 673 deaths including 537
from cancer. The patients' population also displayed 199
second cancers, including 105 cancers of the contralateral
breast. Overall survival at 60 months was 83.8+1.5% and
67.2+1.9% at 120 months.
Univariate analysis of disease-free interval and of overall
survival A total of 74.1+0.9% of the patients were free of- m o mcep mi brea-t cancer -
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Table H Oestrogen and progesterone receptors according to the participating centres
ER PR
Per cent Per cent
Centre n Median Mean (s.em.) ER+ (CI) Median Mean (s.e.m.) PR+ (CI)
1 693 57.0 105.2 (5.7) 76 (76-82) 17.0 81.0 (5.7) 59 (55-63)
2 608 30.0 75.9 (5.1) 76 (73-79) 16.0 49.1 (3.7) 65 (61-69)
3 299 81.0 141.9 (9.5) 84 (80-88) 44.0 95.5 (8.1) 59 (53-65)
4 289 11.5 46.7 (6.6) 54 (48-60) 7.0 19.7 (2.7) 38 (32-44)
5 229 25.0 75.0 (8.5) 64 (58-70) 11.0 124.2 (15.1) 40 (34-46)
6 47 48.0 110.7 (25.5) 75 (40-95) 41.0 99.7 (24.3) 62 (26-88)
7 64 34.0 176.1 (36.7) 70 (58-82) 21.0 %.7 (23.9) 56 (44-68)
8 28 12.5 71.6 (31.2) 46 (27-65) 51.5 141.5 (34.8) 57 (39-75)
ER, oestrogen receptors; PR, progesterone receptors. Positivity if > 10 fmol mg cytosol protein. Cl, confidence interval at 95%; s.e.m..
standard error ofthe mean.
Table m Correlation between steroid receptors and clinical or histological characteristics
ER- ER+ P-value PR- PR+ P-value
Patients n (%} n (%) n % (OX X2)
Age (years)
<35 28 (42) 39 (58) 38 (53) 34 (47)
.35 540 (26) 1506 (74) 0.005 903 (43) 1179 (57) 0.12
Hormonal status
Premenopausal 226 (31) 512 (69) 287 (37) 487 (63)
Post-menopausal 343 (25) 1034 (71) 0.005 655 (47) 728 (53) 0.0001
TNM stage
I 186 (26) 518 (74) 285 (39) 448 (61)
II 324 (26) 901 (74) 0.5 561 (45) 677 (55) 0.001
III 54 (30) 123 (70) 92 (52) 83 (48)
Tumour size (mm)
<20 221 (24) 683 (76) 370 (40) 559 (60)
20-50 251 (36) 724 (74) 0.04 451 (45) 547 (55) 0.036
>50 55 (34) 106 (66) 74 (46) 85 (54)
Histology
Ductal 444 (25) 1310 (75) 731 (41) 1055 (59)
Lobular 18 (19) 74 (81) 0.0001 44 (46) 51 (54) 0.0001
Other 107 (39) 168 (61) 170 (60) 112 (40)
Histological grade
SBR
I 61 (14) 374 (86) 135 (30) 320 (70)
II 236 (22) 843 (78) 0.001 425 (38) 682 (62) 0.001
III 175 (46) 207 (54) 255 (65) 138 (35)
Axillary lymph node
(pN)
None 385 (27) 1057 (73) 652 (44) 813 (56)
1-3 96 (23) 318 (77) 0.03 161 (39) 255 (61) 0.015
>4 35 (36) 62 (64) 50 (54) 43 (46)
ER, oestrogen receptors; PR, progesterone receptors. Positivity if > 10 fmol mg-' cytosol protein. X2, Chi-square test.
disease at 60 months and 64.0+1.1% at 120 months. Some
89.5+0.7% of the patients were free of local recurrences at
60 months, and 83.9+0.9% at 120 months. Overall,
80.0+0.9% of the patients were metastases free at 60
months, 71.4±1.0% at 120 months. The probabilities of
survival according to receptor status in the primary tumour
are given in Figures I (ER), 2 (PR), and 3 (combined ER and
PR). At 60 months (Table IV), the overall survival was
90.1% for ER-positive tumours, 91.5% for PR-positive
tumours and 91.4% when both receptors were positive. All
the differences between positive and negative results are
significant (P<0.01). Significant differences were also
obtained when comparing receptor status and the disease-
free interval or the occurrence of metastases (Figures 4 and
5). The relative risks calculated for ER-negative tumours
were generally slightly higher than the corresponding ones for
PR. For example, the relative nrsks of death were 1.75 for
ER-negative tumours and 1.68 for PR-negative tumours.
Survival after thefirst metastasis We also sought a potential
predictive value of steroid receptors after a first metastasis.
The univariate analysis shows that both ER and PR have a
favourable influence upon survival after a first metastasis, the
difference between positive and negative groups being
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Figue 1 Overallsurvival by ER status (-E-, ER -Z--, ER-).
1261/422 patients ER ,ER- at risk for 60 months, 482,164
patients ER-/ER- at risk for 120 months.
significant at a level of P<0.0001 for each comparison
(only the ER chart is presented; Figure 6). The median of
overall survival after a first metastasis is 29 months for ER-
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positive and 15 months for ER-negative tumours (RR=2.0),
and 33 and 16 months for PR-positive and-negative tumours
respectively (RR= 1.90).
Multivariate analysis The following variables were intro-
duced in the Cox model: age, menopausal status, clinical
stage, size of the tumour, node involvement, histological type
and grade of the tumour and steroid receptors. We have
chosen a cut-off of 35 years for the age groups, in accordance
with the results of several studies (Adami et al., 1986; Host
and Lund, 1986), showing that the differences in overall
survival are at a maximum when using that cut-off. The
influence of these factors on disease-free interval, occurrence
of metastases and survival was evaluated in a forward
stepwise regression. The results for the three models are
presented in Table V. For each factor, the entry step number,
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Figure 2 Overall survival by PR status (---, PR-; -O-, PR-).
1017680 patients PR-/PR- at risk for 60 months, 351'285
patients PR- PR- at risk for 120 months.
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Figure 4 Metastasis-free survival according to ER status (-U-,
ER-; -E-, ER-). 1213/369 ER-/ER- at risk for 60 months,
436/155 patients ER- ,ER- at risk for 120 months.
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Fue 3 Overall survival by combined ER and PR status (-O-,
ER-PR-; -*-, ERPR-; --, ER-PR-;-A-, ER+PR-). 922
340 311, 51 patients ER PR+/ER- PR-/ER PR-/ER- PR-
at risk for 60 months, 321/138/142/20 patients ER PR-/ER-
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Figue 5 Metastasis-free survival according to PR (--, PR-;
-El-, PR+). 911/634 PR+/PR- at risk for 60 months, 318/264
patients PR+ (PR- at risk for 120 months.
Table IV Five and 10 years' results
Survival (%M Metastasis-free (%) DF (%}
5 Sears 10 years 5 years 10 years 5 years 10 years
ER*
ER- 75.9 (1.8) 63.4 (2.2) 72.1 (2.2) 65.0 (2.2) 66.2 (2.0) 58.0 (2.2)
ER- 90.1 (0.8) 75.8 (1.3) 82.2 (1.0) 73.3 (1.2) 76.4 (1.1) 65.8 (1.3)
PR*
PR- 80.3 (1.3) 66.7 (1.7) 75.9 (1.4) 67.6 (1.7) 69.7 (1.5) 60.6 (1.7)
PR- 91.5 (0.8) 77.2 (1.4) 82.9 (1.1) 74.4 (1.4) 77.3 (1.2) 66.3 (1.5)
ER and PR**
ER-PR- 91.4 (0.9) 76.7 (1.5) 82.4 (1.2) 73.4 (1.5) 77.1 (1.3) 66.1 (1.6)
ER-PR- 89.0 (4.0) 75.6 (6.5) 81.7 (5.0) 75.9 (6.3) 71.5 (5.9) 66.0 (6.7)
ER-PR- 87.2 (1.7) 73.9 (2.5) 82.0 (1.9) 72.9 (2.4) 75.1 (2.2) 65.4 (2.6)
ER-PR- 74.2 (2.0) 61.6 (2.4) 70.2 (2.1) 63.0 (2.3) 64.9 (2.2) 55.8 (2.5)
DF, Disease-free; ER, oestrogen receptors; PR, progesterone receptors. Positivity if.10 fmol mg-' cytosol protein. *All P-valuesless than 0.01
for the three criteria. **All P-values less than 0.01 testing for heterogeneity and between the group ER PR and ER-PR-.
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Fugwe 6 Survival after a first metastasis according to ER status
(-x-, ER-; -[1-, ER+). 116/23 ER'/ER- at risk for 36 months.
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Fugwe 7 Relative risk of metastasis according to ER status.
Annual observed and calculated risks with a Log-time dependent
function (Cox non-proportional hazard model).
the relative risk and its confidence interval are displayed. The
diseaw-free interval is reduced for patients under 35 years,
for patients with positive nodes or large tumour size or high
SBR grade and when the tumours are ER negative. PR status
has no statistical significance regarding the disease-free
interval.
The risk of developing metastases increases for patients
under 35 years, for positive lymph nodes, for large tumour
size, for high SBR grade and for ER-negative tumours.
Again, PR status has no prognostic value in this context.
With regard to the mortality risk through breast cancer, the
significant variables of the Cox model were: menopausal
status, high clinical stage, large tumour size, positive lymph
nodes, high SBR grade and ER negativity. PR status was
found to be non-significant. No significant differences in the
relative risks associated to the ER or PR status were found
among premenopausal vs post-menopausal patients.
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Fige 8 Relative nrsk of death according to ER status. Annual
observed and calculated risks with a time-dependent function
(Cox non-proportional hazard model).
Table V Adjusted relative risksa with their 95% confidence interval (Cox model)
Disease-free Metastasis-free
Variable Esn survival Esn survival Esn Survival
Histological grading 1 1 I
(SBR) 1 1 1
I 2.09 (1.61-2.72) 2.32 (1.69-3.18) 2.45 (1.71-3.50)
II 2.50 (1.57-3.98)* 2.86 (1.67-4.88)* 2.80 (1.54-5.07)*
III
Axillary node status 2 2 2
(pN) 1 1 I
None 1.56 (1.28-1.89) 1.85 (1.50-2.31) 1.65 (1.30-2.08)
1-3 2.29 (1.36-3.86) 2.99 (1.77-5.17) 3.23 (1.82-5.69)
>3
Tumour size 3 3 3
<20 mm 1 1 1
20-50 mm 1.46 (1.22-1.74) 1.56 (1.27-1.97) 1.37 (1.06-1.76)
>50 mm 2.05 (1.31-3.22) 2.06 (1.26-3.38)* 1.90 (1.07-3.34)
Age (years) 4 4
>35 1 1
<35 2.78 (1.91-4.03) 2.78 (1.85-4.17) NS
ER status 5 5 4
Positive 1 1 1
Negative 1.35 (1.13- 1.61) 1.45 (1.19- 1.75) 1.85 (1.55- 1.95)
TNM stage 5
I NS NS 1
II 1.38 (1.05-1.82)
mn 1.49 (1.01-2.70)*
Hormonal status 6
Premenopausal 1
Post-menopausal NS NS 1.27 (1.02-1.58)
aRelative risks are referred to the bestprognosis group. Esn, entry step number. ER, oestrogen receptor, Positivity if > 10 fmol mg- cytosol
protein. NS, not significant. *Not significant with the upper group.
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Evolution of the relative risk associated to ER status with
elapsed time As Figures 1 and 4 show a trend for the
prognostic value of ER status to decrease with elapsed time,
we have thus studied a model fitting this observation. For
this purpose, we have introduced a dependence of time in the
Cox model for the risk associated to ER status. This time-
dependent model results in a better fitting of the data
(P<0.001) than the proportional hazard model. Figures 7
and 8 represent the time-dependent evolution of the relative
risks of developing metastases or of death according to ER
status. The relative risk of death (4.68) for ER-negative
tumours at diagnosis tends towards 1 after 8 years of follow-
up. The relative risk of developing metastases linked to ER
status decreases rapidly during the first 2 years.
Prognostic value of ER and PR in low-risk patients A total
of 960 patients were older than 35 years with negative lymph
nodes, a tumour size less than 50 mm and SBR grade I or H.
The disease-free survival was shorter among patients with
ER-negative tumours (RR=1.34, P=0.02). The metastases-
free survival was also shorter for ER-negative tumours
(RR= 1.37, P=0.02). In both cases, PR status showed no
prognostic value. The overall survival for these low-risk
patients was found to be significantly different according to
ER and PR status. The relative risks for ER-negative
tumours was 1.62 (P=0.006) and 1.36 (P=0.003) for PR-
negative tumours.
Discus
The present report is a multicentric study, with inherent
advantages and pitfalls. Among the advantages are the large
number of patients included in the study, the extensive
follow-up and the absence of intervening adjuvant therapies.
Conversely, since the data rely essentially upon the earliest
steroid receptor assays performed for breast cancer manage-
ment, one might question whether they are biased by a
selection oflarge tumours because of technical requirements.
As expected, when compared with recent studies displaying
the pathological sizes with the same cut-off, a difference is
observed in the proportions of TI and T2 or more tumours.
Our series include a smaller proportion of small tumours and
more tumours over 20 mm than the recent ones (Mathiesen et
al., 1991; Stal et al., 1992). Nevertheless, the observed
survival rate for metastases-free patients in our series is
similar to the statistics of the F&deration Nationale des
Centres de Lutte Contre le Cancer (72% at 5 years and 53%
at 10 years; Enquete Permanente Cancer, 1991).
Significant differences appeared between variable means
among the different participating centres. Some of them can
be ascribed to regional differences in patient and medical
behaviour relating to the early diagnosis and management of
breast cancer. For example, the series from centre number 2
shows the youngest and thus the highest premenopausal
proportion of patients; the series from centre number 5 only
includes node-negative patients since all the node-positive
ones were discarded owing to adjuvant chemotherapy.
Overall, it is conceivable that this heterogeneity may bring
more statistical inferences than less dispersed series for the
general population.
With regard to the data derived from laboratory work,
two main points can lead to heterogeneous results:
histological grading and receptor assays. Centre number 3
certainly shows the highest proportion of grade III tumours,
but this is caused by a preselection of tumours of bad
prognosis at the very beginning of the study. The observed
variability among the proportion of the three histological
grades from the different centres remains within the limits
previously described in a multicentric study of SBR grading
(Jacquemier et al., 1981).
All steroid receptor assays were performed according to
the same protocol, which was consequently published for the
new groups intending to carry out the technique in their
laboratories (Martin et al., 1981). However, the percentage of
ER-positive tumours varies widely between centres, probably
owing to differences in technical skills in the beginning of
receptor assays. But, allowing for their relatively small
number of patients and the fact that receptor results were
treated as discontinuous variables (positive/negative) in the
statistical analysis, one might consider that their relative
weight has thus been reduced.
Our statistical analysis of the optimal cut-off to separate
positive and negative subgroups led to a value of
8 fmol mg-' cytosol protein for both receptors. For
simplicity, we have preferred to keep the widely accepted
cut-off of 10 fmol mg-' cytosol protein. A search for a
pejorative cut-off in the elevated concentrations of ER and
PR showed no significant differences up to 1000 fmol mg-'
protein. Our series shows a better prognostic value for
oestradiol receptor than for progesterone receptor in
univariate analysis, in contrast with several previous studies
(Thorpe et al., 1987; Gelbfish et al., 1988; Stal et al., 1992),
but the differences between the relative performances of the
two receptors remain small nevertheless.
Multivariate analysis of the prognostic value of steroid
receptors has been performed in 11 previous studies selected
for their long follow-up and relatively large series ofpatients.
Many of them addressed subgroups of patients, node-
positive: Clark et al. (1993); node-negative: Thorpe et al.
(1987), Silvestrini et al. (1995); patients under 50 years: Stal et
al. (1992); infiltrating ductal carcinomas: Spyratos et al.
(1989). Other studies presented results from unselected
patients but with a mixed population receiving or not
receiving systemic adjuvant therapy: Haybittle et al., (1982),
Chevallier et al. (1988), Aaltomaa et al. (1991), Gelbfish et al.
(1988), Mathiesen et al. (1991). Only the study by Todd et al.
(1987), based on the former patient population of Haybittle,
displays results from an important group of primary breast
cancers without adjuvant therapy and with a relatively long
follow-up, however PR was not studied. The criteria
introduced into the Cox regression model also vary: all the
studies include the clinical or pathological size of the tumour
and the degree of invaded lymph nodes. But, for other
classical prognostic parameters, such as histological grade,
only 7/11 of the studies have included the SBR or a form of
histological classification (nuclear pleomorphism, mitotic
index); the other studies comprised adjuvant therapies or
proliferation criteria such as ploidy, S-phase or tritiated
thymidine incorporation. Moreover, the varying number of
criteria in the different Cox models, from four (Aaltomaa et
al., 1991) to ten (Chevallier et al., 1988), may explain the
diverse conclusions obtained. But, when both ER and PR
were tested in the Cox model, a majority (7j9) of the studies
concluded a better significance or a unique significance of PR
and 3/11 showed a prognostic value for ER alone or for both
receptors. It can be observed that the prognostic value of PR
was particularly evidenced when the patients received
adjuvant treatment.
The ER vanishing prognostic value, reaching a non-
significant relative risk between negative and positive
tumours during the follow-up, is difficult to analyse. A
similar trend was previously described by Spyratos et al.
(1989) in a study of 1262 patients from the Centre Rene
Huguenin. Two kinds of explanation can be proposed: either
this reflects intrinsic biological properties of the cancer cells
evolving towards hormone resistance, or it is caused by
intervening therapies used to control metastatic spreading.
The main conclusion that can be drawn from our study is
that, by multivariate analysis, steroid receptor status has a
relatively limited predictive value when compared with the
well-established prognostic criteria of early breast cancer.
Steroid receptor assays in breast tumours represent the very
first step of a general strategy to decipher the biological
behaviour of human breast cancer for clinical purposes. An
array of biological prognostic factors (proliferation markers,
growth factors, proteases, oncogenes . . .) has since been
proposed. To this date, none of them has gained generalogen and progesisrne_ ceptr and breast cmnew
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acceptance for clinical practice. Steroid receptor status,
although an imperfect predictor of patients' outcome, still
remains the only single biological parameter in use to suggest
therapeutic directives for subgroups of breast cancer patients.
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